Roche looks to Brazil for R&D
This article was originally published in Scrip
Rocheis to screen the Brazilian biotech sector for potential R&D partnerships, the company has told Scrip. Fundação Biominas, a private institution specialising in promoting "bio-business" in Brazil, has been contracted by Roche Brazil to identify opportunities in the country. Areas of interest will include oncology, inflammatory diseases, virology and central nervous system diseases, which make up the company's core business.
You may also be interested in...
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.